LAUSR

Abstract Objective The aim of the study is to analyse variations in the treatment of medulloblastoma, the most common childhood brain tumour, and its impact on survival over the past two decades, as well as its clinical and pathological features. Patients and methods Survival analysis of all patients under 14 years old diagnosed with medulloblastoma between January 1990 and December 2013 in a Paediatric Oncology Unit. Results Sixty-three patients were diagnosed and treated for medulloblastoma, with a median follow-up of 5.1 years (range 0.65–21.7 years). The overall survival (OS) at 3 and 5 years was 66 ± 13% and 55 ± 14%, respectively. The OS at 5 years was 44 ± 25% in patients diagnosed in the 1990s, showing an increase to 70 ± 23% (P = .032) since 2000. Clinical prognosis factors were included in the logistic regression model: age (P = .008), presence of metastases and/or residual tumour (P = .007), and receiving chemotherapy with radiotherapy after surgery (P = .008). Statistically significant differences were observed for all of them. Conclusion In our institution there has been a significant increase in medulloblastoma survival in the last decades. Multivariate analysis showed that this improvement was not related to the date of diagnosis, but with the introduction of chemotherapy in adjuvant treatment. This study confirmed that clinical factors significantly associated with worse outcome were age and presence of metastases at diagnosis.